Bristol-Myers Squibb, a top 50 big pharma company entered into a worldwide, nonexclusive pharma licensing partnership with Vical Incorporated of Vical’s patented platform DNA immunization technology and its Vaxfectin adjuvant for use in the production of antibodies.
Under this pharma licensing agreement, Bristol-Myers Squibb will use Vical’s technology to generate antibodies with potential therapeutic uses in humans.
Vical will also provide specified quantities of the Vaxfectin adjuvant to Bristol-Myers Squibb from time to time as detailed in the pharma licensing agreement.
Financial terms of this pharma licensing agreement were not disclosed.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Bigp harma Partnering Yearbook 2013
View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity